KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Raw Materials: 2018-2019

Historic Raw Materials for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Dec 2019 value amounting to $172.2 million.

  • Amneal Pharmaceuticals' Raw Materials was N/A to $162.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $162.7 million, marking a year-over-year change of. This contributed to the annual value of $172.2 million for FY2019, which is 5.23% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Raw Materials of $172.2 million as of FY2019, which was down 5.23% from $181.7 million recorded in FY2018.
  • Amneal Pharmaceuticals' 5-year Raw Materials high stood at $181.7 million for FY2018, and its period low was $172.2 million during FY2019.
  • Over the past 2 years, Amneal Pharmaceuticals' median Raw Materials value was $176.9 million (recorded in 2018), while the average stood at $176.9 million.
  • Data for Amneal Pharmaceuticals' Raw Materials shows a maximum YoY declined of 5.23% (in 2019) over the last 5 years.
  • Yearly analysis of 2 years shows Amneal Pharmaceuticals' Raw Materials stood at $181.7 million in 2018, then declined by 5.23% to $172.2 million in 2019.